reference/1015325

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1015325

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	4750
issn	1527-7755 0732-183X
issueIdentifier	30
pageRange	4743-4750
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	4743
bibliographicCitation	Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20;25(30):4743–50. doi: 10.1200/jco.2007.12.3026. PMID: 17909199.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fdf33551ca9897babd7762038eb3f609 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5be7adfdad7b552c2c84e8de9643c812 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e66ecc1eac69d2f230d97d924ca291d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a31f0418368d2ac2ff6640c1b333d53 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eccc6187008231a130f692ca8c009d44 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3cc21d3835588cb7c038591c2f3fce39 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89eb4272010f89dacfb9d75aad77d9c9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c22b38f2532c87c617db9ebe66c0c8a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbe26a0aed3fc626b9ea497bbb47e2a0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f77e499ba492d4ae4b0b41f28b87a073
date	2007-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1200/jco.2007.12.3026 https://pubmed.ncbi.nlm.nih.gov/17909199
isPartOf	https://portal.issn.org/resource/ISSN/0732-183X https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer
discusses	http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0493669 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0443627
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D009364Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D008175Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D043823Q000008 http://id.nlm.nih.gov/mesh/D000068258 http://id.nlm.nih.gov/mesh/D000911Q000008 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D061067 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D018287Q000188 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D002282Q000188 http://id.nlm.nih.gov/mesh/D002282Q000473 http://id.nlm.nih.gov/mesh/D011799Q000008 http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D015996 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000077143 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D018287Q000473 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D009364Q000473 http://id.nlm.nih.gov/mesh/D000069347 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D000230Q000473 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D000230Q000188 http://id.nlm.nih.gov/mesh/D006147Q000031
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176870 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7969 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_714b3f52d8149c3277181d9513b93112 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127377427 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851

Total number of triples: 89.